European Journal of Cancer · 2019 · 72 citations · 20 references
PharmacyOncologyPharmacotherapyImmuno-oncology PharmacotherapyMolecular OncologyTumor MicroenvironmentCancer ImmunotherapyImmunotherapy SafetyLung CancerPharmacodynamics Of ImmunotherapiesToxicity ManagementToxicity Risk AssessmentCancer Therapy-related Pulmonary ToxicityNon-small Cell Lung Cancer ImmunotherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer Treatment
20
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +15
Julie R. Brahmer, Charles G. Drake, Ira Wollner et al. · Journal of Clinical Oncology · 2010 · 2.9K citations · Full text
Medicine, Oncology, Pharmacology +17